In the dose expansion, the overall median duration of stable disease was 2.0 months (range, 0.5–12.9) overall, 3.9 months (range 1.9–6.1) among patients with WDLPS, 2.0 months (0.9–6.9) among patients with DDLPS, 1.8 months (0.5–11.9) among patients with GBM, 3.3 months (0.9–12.9) among patients with other solid tumors, 2.0 months (0.9–4.0) among patients with ER + PR+ breast cancer, and 1.4 months (0.9–3.8) among those with ER + PR– breast cancer. This evidence concerns the gene ESR1 and breast cancer.